AstraZeneca (LON:AZN) received a GBX 5,400 ($70.56) price target from equities researchers at UBS Group in a research note issued to investors on Thursday, Borsen Zeitung reports. The firm presently has a “sell” rating on the biopharmaceutical company’s stock. UBS Group’s price objective indicates a potential downside of 21.80% from the stock’s current price.
AZN has been the topic of a number of other reports. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research report on Thursday. Morgan Stanley upped their price target on SYSCO from $69.00 to $72.00 and gave the company an “equal weight” rating in a research report on Tuesday, May 7th. HSBC cut easyJet to a “hold” rating in a research report on Tuesday, April 2nd. Goldman Sachs Group set a €76.30 ($88.72) price target on Stroeer SE & Co KGaA and gave the company a “buy” rating in a research report on Thursday. Finally, Bryan, Garnier & Co reiterated a “neutral” rating on shares of AstraZeneca in a research report on Wednesday, July 3rd. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of GBX 6,582.35 ($86.01).
Shares of AZN traded up GBX 55 ($0.72) on Thursday, reaching GBX 6,905 ($90.23). 2,000,678 shares of the stock traded hands, compared to its average volume of 2,310,000. The firm has a market cap of $90.58 billion and a price-to-earnings ratio of 36.34. The company has a debt-to-equity ratio of 179.66, a quick ratio of 0.57 and a current ratio of 0.75. AstraZeneca has a 12 month low of GBX 5,312 ($69.41) and a 12 month high of GBX 6,634 ($86.68). The stock’s 50-day moving average is GBX 6,385.84.
In other AstraZeneca news, insider Philip A. J. Broadley acquired 520 shares of AstraZeneca stock in a transaction on Tuesday, April 30th. The shares were bought at an average price of GBX 5,738 ($74.98) per share, with a total value of £29,837.60 ($38,988.11). Also, insider Marc Dunoyer purchased 8,500 shares of the business’s stock in a transaction dated Tuesday, May 7th. The shares were purchased at an average cost of GBX 5,800 ($75.79) per share, for a total transaction of £493,000 ($644,191.82).
AstraZeneca Company Profile
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.